If biotech does rebound, it will likely come this fall when a gaggle of investment banks will be holding biotech investor conferences in September and October, per custom. The medical meeting calendar also gets busy, including important cancer-research meetings scheduled for September and December.

But compared with years passed, the back end of 2004 is not filled with as many clinical and regulatory catalysts that so often attract the attention of investors. Still, there are some potential market-moving events expected in the coming months, which include:

  • Eyetech (EYET) and Pfizer (PFE) bringing their drug Macugen (used to treat vision loss in older people) in front of a Food and Drug Administration advisory panel on Aug. 27.
  • In late September, the FDA is expected to announce an approval decision for Gilead Sciences' (GILD) new combination HIV pill.
  • In October, Maxim Pharmaceuticals (MAXM) is expected to release results from a phase III study of its skin cancer drug Ceplene.
  • Adam Feuerstein writes regularly for RealMoney.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. He invites you to send your feedback.

    If you liked this article you might like


    Goodbye CytRx, Your Game Is Over

    Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results

    Bluebird, Celgene CAR-T Keeps Multiple Myeloma Patients Relapse Free

    'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio